Literature DB >> 6315602

Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas.

L A Jones, C L Edwards, R S Freedman, M T Tan, H S Gallager.   

Abstract

Only 69% (42 of 61) of the documented ovarian tumor specimens received between September 1981 and August 1982 contained 75% or more viable tumor. Of the 42 measured for estrogen receptors (ER) and progesterone receptors (PR), 34 (81%) had estrogen-binding titers. greater than or equal to I fmol/mg of cytosol protein, while 18 (43%) had progesterone-binding titers greater than or equal to 5 fmol/mg of cytosol protein. ER and PR titers were found to be independent of histologic grade, clinical stage, patient age, age at first pregnancy, age at menarche, age at menopause and number of pregnancies. The presence of ER and PR in malignant ovarian tumors suggests that assays positive for these hormones could aid in the selection of patients suitable for hormonal therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315602     DOI: 10.1002/ijc.2910320508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.

Authors:  A García-Velasco; C Mendiola; A Sánchez-Muñoz; C Ballestín; R Colomer; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

2.  Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.

Authors:  S P Langdon; M M Hawkes; S S Lawrie; R A Hawkins; A L Tesdale; A J Crew; W R Miller; J F Smyth
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

3.  17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo.

Authors:  Laura A Laviolette; Kendra M Hodgkinson; Neha Minhas; Carol Perez-Iratxeta; Barbara C Vanderhyden
Journal:  Int J Cancer       Date:  2014-02-25       Impact factor: 7.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.